Prepared for
Healthcare
Hero Finding
Clinical attractiveness is real, but adoption ceilings sit well below the target's bull case once cost gatekeeping and evidence thresholds are priced in.
The lead non-antimicrobial product earns the strongest three-year adoption ceiling. A silver-based antimicrobial product sits behind it. A dual-antimicrobial product sits lower still. Across all three, a majority of nurses cite cost and budget approval as the single decisive barrier, and adoption only steps up materially once price is set well below the entrenched incumbent.
Highest
Lead non-antimicrobial · 3-yr adoption ceiling
Lower
Silver antimicrobial · 3-yr ceiling
Strong
Switch rate at material discount to incumbent
Majority
Cite budget approval as decisive barrier
Study Design
N=247 senior nurses · five Western markets · structured quantitative survey across the test portfolio.
The sample was sized to deliver market-level reads in each of the five target markets, with quotas for facility ownership type, unit volume, and seniority to mirror the buying committees that actually clear vascular access purchases inside public health systems and private specialty chains.
Sample segmentation
Public health system · 174
Private specialty chain · 56
Private independent · 17
Interview guide · core topics
- Current dressing protocols, brand allocation, and antimicrobial usage across exit-site and access-site care
- Clinical attractiveness and patient-benefit ratings across the test portfolio
- Three-year adoption ceilings and market-level switching dynamics
- Price ladder testing versus the entrenched incumbent at multiple price points
- Evidence thresholds, formulary pathways, and procurement gating
- Procedural kit configuration appeal and bundled-purchase economics
- Shower protection unmet need and willingness-to-pay among target units
Recruit criteria
- Senior nurses with five or more years of practice (~½ had 11+ years)
- Direct involvement in vascular access product evaluation, selection, or procurement
- Mix of primary decision-maker, evaluation committee, and clinical advisory roles
- Mid- and high-volume units across public and private settings
Key Findings
What the diligence surfaced.
Six signals reshaped the deal team's view of the bid range, the market sequencing, and the integration plan.
Top
Lead non-antimicrobial · 3-yr ceiling
Lower
Silver antimicrobial · 3-yr ceiling
Strong majority
Agree silver provides effective protection
Majority
Cite cost as decisive adoption barrier
Strong
Switch rate at material price discount
~7 in 10
Sample working in public health systems
01
The lead non-antimicrobial product carries the highest three-year adoption ceiling and the cleanest price story.
Nurses rated the lead non-antimicrobial product attractive enough to support the strongest three-year adoption ceiling among relevant patients in the portfolio. At a material discount to the entrenched incumbent, switching intent landed in a strong majority on average, with mid-volume units highest. The product sits in a category with the lowest evidence threshold and the broadest patient eligibility, making it the clearest near-term revenue lever in the portfolio.
02
Silver antimicrobial demand is real but ceilings sit lower and country variance is wide.
The silver antimicrobial product landed a meaningfully lower three-year adoption ceiling, with two markets materially ahead of the other three. A strong majority of nurses agreed silver provides effective antimicrobial protection at exit sites, but only a minority agreed the indication-specific clinical evidence is strong enough to justify routine use. The category moves on the highest-adoption markets first; the slowest market is a multi-year build.
03
Cost is the single decisive adoption barrier across every market and every product in the portfolio.
A majority of nurses named financial constraints and budget approval as the gating barrier, rising further inside private specialty chains and independent centers. The pattern repeats verbatim for every silver, dual-antimicrobial, and shower-protection SKU tested. The bid model has to underwrite a price posture that sits inside the discount band, not above the incumbent.
04
Price elasticity is steep and the pricing window is narrow.
Switching to the lead product climbed from low single-digits at parity with the entrenched incumbent to a strong majority at a material discount. Mid-volume units recorded the highest switch intent at the discount point, the highest of any segment. The portfolio earns its enterprise value by sitting meaningfully below incumbent list, not by holding premium pricing.
05
Evidence thresholds and procurement gating add 12 to 18 months of friction on antimicrobial SKUs.
A meaningful share of nurses tied silver-product adoption explicitly to comparative-effectiveness evidence versus the entrenched antimicrobial standard, and a similar share to mandatory tender cycles and multi-year supplier contracts. Inside large public systems, formulary inclusion and tender cadence push antimicrobial scale-up beyond the holding period unless the deal team funds an evidence-generation track on day one.
06
Pre-assembled procedural kits are the clearest cross-sell vector inside the portfolio.
Kit configuration testing showed strong appeal for bundles that combine the lead product with consumables and gloves, with optional shower-pouch attachment. Kits are the mechanism that pulls multiple SKUs through a single procurement decision, reducing the per-SKU evidence burden and increasing capture inside high-volume units.
“Cost is the main barrier. It would have to be clinically shown to be better than the incumbent in order to start the conversation.”— Charge Nurse, Community hospital specialty unit
Crosstab · Market Adoption
Three-year adoption ceilings by market and product.
Indexed share of relevant patients each market expects to migrate to each test product within three years, among nurses rating the product clinically attractive. Reindexed to peak market read = 100. Highlighted row = portfolio lead by adoption ceiling.
| Market 2 | Market 5 | Market 3 | Market 1 | Market 4 | |
|---|---|---|---|---|---|
| Lead non-antimicrobial | 87 | 84 | 92 | 100 | 82 |
| Silver antimicrobial | 74 | 69 | 79 | 89 | 47 |
| Dual antimicrobial | 61 | 58 | 66 | 71 | 39 |
| Shower protection | 50 | 47 | 53 | 63 | 35 |
Indexed · blinded valuesTop market leads adoption ceilings on every SKUSlowest market is a multi-year build across the portfolioLead non-antimicrobial tops every market read
Voice of the Buyer
What senior nurses actually said.
Verbatim excerpts from the qualitative track, selected to span facility ownership and decision-maker role across the portfolio.
Private Chain · Budget Gatekeeping
“With our chain, they're very particular with the budget. So I don't think we're going to switch to another provider for that. In terms of infection control, it would be very nice to use, but I don't think the budget would approve it.”
— Nurse Manager, Large national specialty chain
Public System · Tender Friction
“Our trust is a big organization, so changing products or suppliers usually takes a while because it has to go through various bureaucratic processes. It can be done, but the process itself is the barrier.”
— Senior Nurse, Public health system
Public System · Visibility Concern
“The major barrier for many colleagues would be that the dressing is not transparent. You can't directly check the insertion site. Many nursing staff would prefer the classic transparent dressings.”
— Senior Nurse, Public specialty unit
Hospital · Evidence Threshold
“It really comes down to clinical evidence. The cost versus benefit really hasn't been shown to be there with silver-based products in our patient population.”
— Clinical Nurse Specialist, Hospital outpatient unit
Public System · Incumbent Satisfaction
“The dressings we currently use work very well for us. We don't have many infections, so there is not much interest in changing this type of dressing.”
— Senior Nurse, Public specialty unit
Public System · Tender Process
“Purchasing is done mainly through tenders. We are the users, so we can do some sampling, but for actual implementation we still need to test the product first in order to propose it to the purchasing department.”
— Coordinating Nurse, Public specialty unit
Counter-intuitive
The strongest three-year adoption ceiling sits on the non-antimicrobial product, not the silver hero SKU the target leads with in its pitch.
Going in, the deal team expected the silver antimicrobial product to anchor the value story given its margin profile and the target's marketing posture. The data inverted that hierarchy. The lead non-antimicrobial product cleared the highest market-level ceilings, the steepest switch elasticity, and the broadest patient eligibility, while the silver SKU sat behind it on every market read except one. The takeaway is structural: the portfolio's near-term revenue is in the volume product nurses can adopt without a tender cycle, and the antimicrobial story is a longer-dated build that needs evidence funding to clear formulary review.
Strategic Implications
Three priorities from the diligence.
The research grounded the deal team's view on bid posture, market sequencing, and the post-close value-creation plan.
01
Anchor the bid model on the lead non-antimicrobial product, not the antimicrobial story.
The lead non-antimicrobial product carries the highest adoption ceiling, the steepest price elasticity, and the lowest evidence threshold. Underwriting the bid against this product, with the antimicrobial line treated as a longer-dated optionality build, brings the entry multiple into a defensible range and de-risks the early-period revenue ramp.
02
Sequence the market rollout from highest to lowest adoption-ceiling markets.
The top market clears the highest ceilings on every SKU and shows the largest premium-to-mean switch intent. The next two markets follow on antimicrobial demand. The slowest two markets require longer evidence-generation cycles and steeper procurement workarounds, and should be modeled as years three and four of the hold rather than year one.
03
Fund a kit-led commercial motion and an indication-specific evidence track on day one.
Pre-assembled kits are the mechanism that pulls multiple SKUs through a single procurement decision and improves attach rate inside high-volume units. A parallel indication-specific clinical evidence program addresses the meaningful share of buyers who name evidence as the gating barrier on antimicrobial SKUs and is the prerequisite for unlocking the antimicrobial ceiling in the back half of the hold.
Success criteria · 12 months
- Lead product captures meaningful share of relevant patients in top two markets by month 18
- Antimicrobial SKU formulary inclusion across multiple public-system trusts and large IDNs by year 2
- Pre-assembled kit attach rate above one-third inside accounts that adopt any single SKU
- Average realized price holds at the planned discount band to the incumbent's list
Risk register
| Cost gatekeeping caps adoption below model in private specialty chains | HIGH |
| Antimicrobial evidence generation runs longer than holding period | HIGH |
| Slowest-market adoption ceilings remain materially below other markets | MED |
| Tender cycles delay public-system scale-up by 12 to 18 months | MED |
| Opaque-dressing visibility concerns suppress nursing advocacy | LOW |